| octreotide acetate / Generic mfg. |
| Completed | N/A | 61 | Europe | Octreotide-LAR, Sandostatin (Novartis Pharma) | Federico II University | Acromegaly | 12/07 | 12/07 | | |
| Completed | N/A | 100 | Europe | Octreotide-LAR or lanreotide, Sandostatin-LAR (Novartis), Ipstyl (Ipsen), Transsphenoidal adenomectomy | Federico II University | Acromegaly | 06/08 | 06/08 | | |
NCT00789841: Gastrointestinal Motility in Patients With Neuroendocrine Tumors |
|
|
| Completed | N/A | 13 | Europe | Magnetic Tracking System (MTS) and radio-opaque markers | University of Aarhus, Novartis, The Danish Medical Research Council | Neuroendocrine Tumor | 05/10 | 05/10 | | |
| Completed | N/A | 29 | US | Albumin, Intravenous Albumin 25%, Albumin placebo, Normal saline, Midodrine, Midodrine oral tablets, Midodrine placebo, Midodrine placebo pills, Octreotide, Intramuscular Octreotide long acting (LAR), Octreotide placeo, Octreotide placebo (normal saline) intramuscular injection | VA Connecticut Healthcare System, Yale University | Cirrhosis | 08/10 | 08/12 | | |
NCT03017690: Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) |
|
|
| Completed | N/A | 22 | US | | Ipsen | Gastroenteropancreatic Neuroendocrine Tumor | 05/18 | 05/18 | | |
NCT02973204: Circulating Tumor Cells and Tumor DNA in HCC and NET |
|
|
| Completed | N/A | 167 | Europe | Sorafenib, Nexavar, Anatomical Therapeutic Chemical Classification System L01XE05, Radiofrequency ablation (RFA) or surgery, Everolimus, Certican, Afinitor, Votubia, Anatomical Therapeutic Chemical Classification System L01XE10, Lanreotide, Ipstyl, Sandostatin LAR, Octreotide | University of Aarhus, Aarhus University Hospital | Carcinoma, Hepatocellular, Neuroendocrine Tumors | 01/20 | 01/20 | | |
NCT06080204: Real-world Study on Adjuvant Octreotide Therapy in pNETs |
|
|
| Completed | N/A | 411 | NA | Octreotide LAR, Sandostatin | Changhai Hospital | Pancreatic Neuroendocrine Tumor G2 | 04/20 | 04/20 | | |
ChiCTR1800018070: Clinical study of rehoci combined with long-acting octreotide in reducing the risk of rebleeding in patients with cirrhosis and portal hypertension |
|
|
| Not yet recruiting | N/A | 80 | | placebo ;rifaximin ;long acting octreotide ;rifaximin+long acting octreotide | Shanghai Jiao Tong University Affiliated Sixth People's Hospital; Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Self financing | portal hypertension | | | | |
| Terminated | N/A | 76 | US | Pegvisomant, Somavert, Octreotide LAR, Sandostatin, Lanreotide, Somatuline | Cedars-Sinai Medical Center | Acromegaly | 05/22 | 05/22 | | |
| Recruiting | N/A | 70 | Europe | Octreotide, Octreotide LAR | Mario Negri Institute for Pharmacological Research | Autosomal Dominant Polycystic Kidney | 12/24 | 12/24 | | |
